Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Teysuno (gimeracil/oteracil/tegafur)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Nordic Group, Otsuka

Drug class:

Thymidylate synthase inhibitor

Related drugs:

ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	gimeracil/oteracil/tegafur Sensitive: B - Late Trials gimeracil / oteracil / tegafur Sensitive : B	gimeracil/oteracil/tegafur Sensitive: B - Late Trials gimeracil / oteracil / tegafur Sensitive : B
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	gimeracil/oteracil/tegafur Sensitive: B - Late Trials gimeracil / oteracil / tegafur Sensitive : B	gimeracil/oteracil/tegafur Sensitive: B - Late Trials gimeracil / oteracil / tegafur Sensitive : B
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	bevacizumab + gimeracil/oteracil/tegafur Sensitive: B - Late Trials bevacizumab + gimeracil / oteracil / tegafur Sensitive : B	bevacizumab + gimeracil/oteracil/tegafur Sensitive: B - Late Trials bevacizumab + gimeracil / oteracil / tegafur Sensitive : B
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	gimeracil/oteracil/tegafur Sensitive: C3 – Early Trials gimeracil / oteracil / tegafur Sensitive : C3	gimeracil/oteracil/tegafur Sensitive: C3 – Early Trials gimeracil / oteracil / tegafur Sensitive : C3
KRT19 elevation	Non Small Cell Lung Cancer	KRT19 elevation	Non Small Cell Lung Cancer	gimeracil/oteracil/tegafur Sensitive: C3 – Early Trials gimeracil / oteracil / tegafur Sensitive : C3	gimeracil/oteracil/tegafur Sensitive: C3 – Early Trials gimeracil / oteracil / tegafur Sensitive : C3
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	irinotecan + gimeracil/oteracil/tegafur Sensitive: C3 – Early Trials irinotecan + gimeracil / oteracil / tegafur Sensitive : C3	irinotecan + gimeracil/oteracil/tegafur Sensitive: C3 – Early Trials irinotecan + gimeracil / oteracil / tegafur Sensitive : C3
MSI-H/dMMR	Biliary Tract Cancer	MSI-H/dMMR	Biliary Tract Cancer	cisplatin + gemcitabine + gimeracil/oteracil/tegafur Resistant: C4 – Case Studies cisplatin + gemcitabine + gimeracil / oteracil / tegafur Resistant : C4	cisplatin + gemcitabine + gimeracil/oteracil/tegafur Resistant: C4 – Case Studies cisplatin + gemcitabine + gimeracil / oteracil / tegafur Resistant : C4